On July 6, Danaher fell 3.01% in regular trading, trading at $191.13/share, with turnover of $94.04 million. The decline came as Evercore ISI cut its price target on Danaher to $230 from $232, while maintaining its Outperform rating, adding to broader weakness across the Life Sciences Tools & Services sector.

The latest target cut is part of a sustained pattern of downward revisions from multiple investment banks in recent months. HSBC slashed its target from $270 to $230, Argus reduced its from $265 to $230, Barclays trimmed from $250 to $230, and Jefferies lowered from $265 to $240 — all while maintaining buy-equivalent ratings. The current consensus target stands at $241.95, still well above the current stock price. The systematic compression of price targets reflects recalibrated growth expectations for the company.

Sector peer Thermo Fisher Scientific fell 2.5% on the same session, indicating broad-based selling pressure in life sciences tools. Among sector constituents, Bio-Techne declined 0.25%, Tempus AI fell 1.28%, while Seer Inc. surged 37.96% and Illumina edged up 0.1%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)